CN108514119A - A kind of product of composition, its application and fat-reducing, increasing flesh - Google Patents

A kind of product of composition, its application and fat-reducing, increasing flesh Download PDF

Info

Publication number
CN108514119A
CN108514119A CN201810295675.1A CN201810295675A CN108514119A CN 108514119 A CN108514119 A CN 108514119A CN 201810295675 A CN201810295675 A CN 201810295675A CN 108514119 A CN108514119 A CN 108514119A
Authority
CN
China
Prior art keywords
weight
composition
fat
parts
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810295675.1A
Other languages
Chinese (zh)
Inventor
牟媛
易斌
王曙宾
罗丽莲
肖艳皎
郭珊珊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Scrianen Pharmaceutical Co Ltd
Original Assignee
Beijing Scrianen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Scrianen Pharmaceutical Co Ltd filed Critical Beijing Scrianen Pharmaceutical Co Ltd
Priority to CN201810295675.1A priority Critical patent/CN108514119A/en
Publication of CN108514119A publication Critical patent/CN108514119A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a kind of compositions, including：0.7~6.0 parts by weight of conjugated linoleic acid glyceride；0.04~0.3 parts by weight of Epigallo-catechin gallate (EGCG)；1.0~7.0 parts by weight of medium chain triglyceride；3.0~10.0 parts by weight of lactalbumin.Conjugated linoleic acid glyceride (CLA TG) provided by the invention plays the effect that combustion fat increases flesh by adjusting the ratio of body fat and protein；Epigallo-catechin gallate (EGCG) promotes heat production, increases energetic supersession, increases the decomposition of fat；Medium chain triglyceride has faster hydrolysis infiltration rate；It is combined with lactalbumin, while specifically being matched by said components, have the effect of the weight-reducing of collaboration, while increasing muscle density.

Description

A kind of product of composition, its application and fat-reducing, increasing flesh
Technical field
The present invention relates to health product technology fields, more particularly, to a kind of composition, the product of its application and fat-reducing, increasing flesh.
Background technology
Obesity not only aesthetically brings unlimited puzzlement, but also has certain harmfulness to health, fat The probability that person suffers from the illnesss such as hypertension, coronary heart disease, diabetes, cholecystitis, cholelithiasis and fatty liver is higher than non-obese person, 1997 The World Health Organization (WHO) explicitly points out " fat inherently a kind of disease " in the fat conference in the first whole world.Therefore, lose weight A kind of universal phenomenon is become.
Common method of weight-reducing keeps fit through sport, weight reduction with drugs, lipposuction, diet weight-reducing etc..These common weight-reducing Method effect is often barely satisfactory.Keeping fit through sport, needs are long-term, regularly adhere to, need to spend more muscle power and time, past It is lasting toward being relatively difficult to.Weight reduction with drugs includes the drug for taking appetite-suppressing, the drug for increasing energy expenditure, inhibits enteron aisle digestion The drug etc. of absorption is a kind of weight-reducing mode of prevalence, has certain effect, but often with more or less side effect.Hand Art weight-reducing includes contracting stomach art, stomach bypass, water polo therapy etc. in stomach band, stomach, costly and risky.Crash dieting is compared It is more healthy for weight reduction with drugs, mainly reach fat-reducing effect by controlling the diet of people, but this method needs heavily fortified point Strong willpower could adhere to for a long time, and be easy rebound.Therefore, a kind of safe and effective diet products of exploitation have very Important meaning.
Invention content
In view of this, the technical problem to be solved in the present invention is to provide a kind of composition, composition provided by the invention Have the function of stronger weight-reducing, increase flesh.
The present invention provides a kind of compositions, including：
Preferably, the composition includes：
Preferably, the composition includes：
Preferably, further include one or more of following component：
Beta-hydroxy -1.0~5.0 parts by weight of Beta-methyl calcium butyrate；
0.0001~0.0005 parts by weight of folic acid and/or folic acid derivatives.
Preferably, further include one or more of following component：
Beta-hydroxy -2.0~5.0 parts by weight of Beta-methyl calcium butyrate；
0.0003~0.0005 parts by weight of folic acid and/or folic acid derivatives.
The present invention provides application of the composition described in above-mentioned technical proposal in the product for preparing fat-reducing, increasing flesh.
The present invention provides a kind of products of fat-reducing, increasing flesh, including the composition described in above-mentioned technical proposal.
Preferably, dosage form is one or more of pulvis, tablet, oral solution, granule and capsule.
Preferably, in the pulvis, including the composition described in above-mentioned any one technical solution and 0.1%~2% weight Measure the glidant of percentage.
Preferably, further include the corrigent of 20%~40% weight percent in the pulvis.
Compared with prior art, the present invention provides a kind of compositions, including：0.7~6.0 weight of conjugated linoleic acid glyceride Measure part；0.04~0.3 parts by weight of Epigallo-catechin gallate (EGCG)；1.0~7.0 parts by weight of medium chain triglyceride；Whey 3.0~10.0 parts by weight of albumen.Conjugated linoleic acid glyceride (CLA-TG) provided by the invention is by adjusting body fat and egg The ratio of white matter plays the effect that combustion fat increases flesh；Epigallo-catechin gallate (EGCG) promotes heat production, increases energetic supersession, Increase the decomposition of fat；Medium chain triglyceride has faster hydrolysis infiltration rate；It is combined with lactalbumin, while by above-mentioned Component specifically matches, and has the effect of the weight-reducing of collaboration, while increasing muscle density.
Specific implementation mode
The present invention provides a kind of composition, the product of its application and fat-reducing, increasing flesh, those skilled in the art can use for reference Present disclosure is suitably modified technological parameter realization.In particular, it should be pointed out that all similar substitutions and modifications are to this field skill It is for art personnel it will be apparent that they shall fall within the protection scope of the present invention.The method of the present invention and application have passed through Preferred embodiment is described, related personnel obviously can not depart from the content of present invention, in spirit and scope to the side of this paper Method and application are modified or suitably change and combine, to realize and apply the technology of the present invention.
The present invention provides a kind of compositions, including：
Composition provided by the invention includes the conjugated linoleic acid glyceride of 0.7~6.0 parts by weight；Preferably include 0.7~ The conjugated linoleic acid glyceride of 3.0 parts by weight；More preferably include the conjugated linoleic acid glyceride of 0.7~1.5 parts by weight；It can be with Include the conjugated linoleic acid glyceride of 1.2~3.0 parts by weight.
Conjugated linoleic acid (CLA) plays the effect that combustion fat increases flesh by adjusting the ratio of body fat and protein.It is just As a commanding officer, protein is concentrated in musculature, allows fat to enter metabolic pathway as early as possible, by activating aliphatic acid Oxidizing ferment promotes the oxidation of fat, to adjust fat metabolism.CLA is after being absorbed into vivo, meeting precedence partition to abdomen fat Fat tissue, followed by subcutaneus adipose tissue and muscle.In brief, conjugated linoleic acid can preferentially cut belly fat, then It is the fat at the positions such as arm, leg and buttocks.Conjugated linoleic acid (CLA) is a series of double bond linoleic acid, can be effectively reduced Ratio of the body fat tissue relative to lean tissue, really reduces to fat meat, and lean meat ratio is made to increase, and such benefit is Lean meat is more, and internal metabolic capabilities are higher, then forms benign cycle, and weight-reducing will more easily reach target.The sub- oil of conjugation Acid glyceride (CLA-TG) is then a kind of grease containing CLA structures, and compared with aliphatic acid, CLA-TG has more excellent parent Lipid." conjugated linoleic acid glyceride " is classified as new resource food by the Ministry of Public Health's No. 12 bulletin in 2009.Due to feed fat powder The special molecular structure of acid, it is easy to aoxidize, is rancid, for effective protection CLA and CLA-TG, avoid being broken by external environment It is bad, and also to change physical form, fat-soluble CLA-TG is transformed into cold water-dispersible solid powder, i.e., conjugation is sub- The microcapsule powder of olein.
Conjugated linoleic acid glyceride of the present invention first can be prepared into conjugated linoleic acid glyceride using existing technology Microcapsule powder reuses, or directly buys commercially available conjugated linoleic acid glyceride microcapsule powder and use, and the present invention is to this without limiting. When using conjugated linoleic acid glyceride microcapsule powder, the dosage of content, i.e. conjugated linoleic acid glyceride in the composition meets The parts by weight of above-mentioned restriction.
Composition provided by the invention includes the Epigallo-catechin gallate (EGCG) of 0.04~0.3 parts by weight；It is preferred that Include the Epigallo-catechin gallate (EGCG) of 0.04~0.2 parts by weight；More preferably the table including 0.04~0.1 parts by weight does not have Infanticide catechin and gallate；The most preferably Epigallo-catechin gallate (EGCG) of 0.04~0.08 parts by weight.
Epigallo-catechin gallate (EGCG) (Epigallo Catechin Gallate, abbreviation EGCG) is green tea tea Most effective active constituent in polyphenol has antibacterial, antiviral, anti-oxidant, anti arteriosclerosis, antithrombus formation, anti-angiogenic increasing Raw, anti-inflammatory and antitumor action.EGCG has 4 main mechanisms to weight-reducing：1. promoting heat production, increase energetic supersession, increases fat The decomposition of fat promotes the oxidation of aliphatic acid；2. inhibiting Energy intaking, Adipocyte Differentiation and fat is inhibited to generate；3. regulating and controlling thin Element, phylaxin inhibit gluconeogenesis, improve insulin sensitivity；4. reducing lipid to absorb, increase lipid excretion.Epigallocatechin gallate The protein kinase (enzyme needed for burn fat) that catechin gallate (EGCG) can be activated with activating phosphatase adenosine, participates in In a series of cascade reaction of fat metabolism, accelerate the combustion decomposition of fat as a combustion adjuvant.In the present invention, table is not eaten Sub- catechin and gallate can also effectively improve the fat-reducing effect of composition.The present invention is to its source without restriction, city It sells.
Composition provided by the invention includes the medium chain triglyceride of 1.0~7.0 parts by weight；Preferably include 1.0~3.0 weights Measure the medium chain triglyceride of part；More preferably include the medium chain triglyceride of 1.0~2.3 parts by weight；Can also include 1.5~3.0 The medium chain triglyceride of parts by weight.
Medium chain triglyceride (Medium-chain triglyceride, MCT) is commonly referred to as medium chain fatty acid The triglycerides that (Medium chain fatty acid, MCFA) is made of main component, be naturally occurring in palm-kernel oil, It is one of source of dietary fat in the food and breast milk such as coconut oil, main component is " Glycerin, mixed triester with caprylic acid capric acid ".MCT has water Solution absorbs fast feature, is directly transferred to liver metabolism by portal vein after being absorbed by intestinal cell, and MCT enters mitochondria Outer membrane does not depend on carnitine transferase, keeps its oxidation rapider.Human energy metabolism can be improved in intake MTC, promotes lipolysis.In Chain triglyceride (MCT) is a kind of special fat, helps to enhance satiety, while promoting the burning of calorie again.It is inhaled It receives simply, does not depend on various enzymes and carrier；It is short to absorb path, go directly liver；Metabolism is fast, and energy is provided in liver direct oxidation, It is exactly " simple, efficient " in brief.Emphasis is will not to synthesize body fat, relies on this point, is applied to build management food In star's dispensing.
In the present invention, the medium chain triglyceride first can use prior art preparation at medium chain triglyceride microcapsule powder It reuses, or directly buys commercially available medium chain triglyceride microcapsule powder and use, the present invention is to this without limiting.Chain is sweet in use When oily three ester micro capsule powder, the dosage of content, i.e. medium chain triglyceride in the composition meets above-mentioned parts by weight.
Composition provided by the invention includes the lactalbumin of 3.0~10.0 parts by weight；Preferably include 3.0~5.0 weight The lactalbumin of part；More preferably include the lactalbumin of 3.0~4.0 parts by weight；It can also include the breast of 3.5~4.5 parts by weight Albumin.
Lactalbumin (whey protein) is referred to as " king of albumen " in nutrition, is the one kind extracted from milk Protein, purity is high, amino acid ligand ratio is appropriate, all essential amino acids needed rich in human body.The paddy that lactalbumin is rich in Glutamine, branched-amino, the aminoacid ingredient needed for a variety of muscle such as coenzyme, it is easy to be absorbed by the body, rapid supplement is internal The nutrition of loss is generally acknowledged one of human body good protein replenishers.
The present invention to its source without limit, it is commercially available.
Composition described in the one of technical solution of the present invention includes：
Composition described in the one of technical solution of the present invention includes：
Composition described in the one of technical solution of the present invention includes：
Conjugated linoleic acid glyceride (CLA-TG) provided by the invention is risen by adjusting the ratio of body fat and protein Increase the effect of flesh to combustion fat；Epigallo-catechin gallate (EGCG) promotes heat production, increases energetic supersession, increases point of fat Solution, medium chain triglyceride have faster hydrolysis infiltration rate, are combined with lactalbumin, while specifically being matched by said components Than having the effect of the weight-reducing of collaboration, while increasing muscle density.Material selected by above-mentioned composition is safe and healthy, and leads to It crosses and plays different effects, reach good fat-reducing, increasing flesh effect.
According to the present invention, the composition further includes one or more of following component：
Beta-hydroxy -1.0~5.0 parts by weight of Beta-methyl calcium butyrate；
0.0001~0.0005 parts by weight of folic acid and/or folic acid derivatives.
The present invention to its source without limit, it is commercially available.
Composition of the present invention preferably further includes beta-hydroxy-Beta-methyl calcium butyrate of 1.0~5.0 parts by weight；More preferably It further include beta-hydroxy-Beta-methyl calcium butyrate of 2.0~5.0 parts by weight；Beta-hydroxy-β-first of most preferably 3.0~5.0 parts by weight Base calcium butyrate.
Beta-hydroxy-Beta-methyl calcium butyrate (HMB-Ca) can be used for promoting muscle growth, strengthen immunity that it is solid to reduce internal courage Alcohol and low-density lipoprotein (LDL) level are to reduce the generation of coronary heart disease and angiocardiopathy, moreover it is possible to enhance human body nitrogen fixing capacity, Maintain vivo protein horizontal.
Composition of the present invention preferably further includes the folic acid and/or folic acid derivatives of 0.0001~0.0005 parts by weight； Further include more preferably 0.0003~0.0005 parts by weight folic acid and/or folic acid derivatives；Most preferably further include 0.0004~ 0.0005 parts by weight folic acid and/or folic acid derivatives.
The folic acid derivatives are that formyl tetrahydrofolic acid, metafolin, folic acid officinal salt, folic acid or folic acid are pharmaceutically acceptable It is one or more in the active metabolite of salt and the substance that can be metabolized and/or generate in vivo folic acid.
Folic acid is a kind of very important water soluble vitamin, into after human body, under the reduction of folic acid reductase Become tetrahydrofolic acid, tetrahydrofolic acid ginseng can be closely related with internal many important biochemical processes, coenzyme can be used as to participate in core The formation of purine and pyrimidine, directly affects synthesis and the amino acid metabolism of DNA, to cell division, proliferation and tissue in acid synthesis Growth has extremely important effect.
Beta-hydroxy-Beta-methyl calcium butyrate and folic acid and/or folic acid derivatives are added for the discovery of the present inventor's creativeness It states in conjugated linoleic acid glyceride, Epigallo-catechin gallate (EGCG), medium chain triglyceride and lactalbumin composition, it can To significantly improve the synergistic effect of composition significantly, there is good weight-reducing and increasing flesh effect.
Composition described in the one of technical solution of the present invention includes：
Composition described in the one of technical solution of the present invention includes：
Composition described in the one of technical solution of the present invention includes：
The present invention provides the preparation methods of the composition described in above-mentioned technical proposal, and above-mentioned raw materials are straight according to parts by weight Mixing is connect, is method well known to those skilled in the art, the present invention is to this without limiting.
The present invention provides application of the composition described in above-mentioned technical proposal in the product for preparing weight-reducing.
The present invention provides application of the composition described in above-mentioned technical proposal in preparing the product for increasing flesh.
According to the present invention, the product of the weight-reducing is food, drug or health products.
According to the present invention, the product for increasing flesh is food, drug or health products.
Specifically, it includes acceptable dispensing in composition and food of the present invention to lose weight, increase the food of flesh.
Weight-reducing, the health products for increasing flesh include acceptable auxiliary material in composition and health products of the present invention.
Weight-reducing, the drug for increasing flesh include acceptable auxiliary material in composition and drug of the present invention.
The present invention provides a kind of products of fat-reducing, increasing flesh, including the composition described in above-mentioned technical proposal.
Preferably, dosage form is one or more of pulvis, tablet, oral solution, granule and capsule.
In the present invention, the composition in the pulvis, including described in above-mentioned technical proposal and 0.1%~2% weight hundred Divide the glidant of ratio.
The glidant is preferably selected from one or more of silica, calcium silicates and calcium monohydrogen phosphate.The present invention is to it Source is commercially available without limiting.
In the present invention, preferably further include the corrigent of 20%~40% weight percent in the pulvis.
The corrigent is selected from one or more of fruit powder, sugar alcohol.The present invention to its source without limit, it is commercially available i.e. It can.
The present invention provides a kind of compositions, including：0.7~6.0 parts by weight of conjugated linoleic acid glyceride；Epigallocatechin gallate 0.04~0.3 parts by weight of catechin gallate；1.0~7.0 parts by weight of medium chain triglyceride；3.0~10.0 weight of lactalbumin Measure part.Conjugated linoleic acid glyceride (CLA-TG) provided by the invention is played by adjusting the ratio of body fat and protein Fire the effect that fat increases flesh；Epigallo-catechin gallate (EGCG) promotes heat production, increases energetic supersession, increases the decomposition of fat； Medium chain triglyceride has faster hydrolysis infiltration rate；It is combined with lactalbumin, while specifically being matched by said components, Have the effect of the weight-reducing of collaboration, while increasing muscle density.In order to further illustrate the present invention, with reference to embodiments to this The product for inventing the composition provided, its application and strengthen immunity, improvement allergy is described in detail.The material that the present invention uses Material is all common commercially available product, can all be bought in market.
Examples 1 to 6；Comparative example 1~7
A kind of composition, including component and parts by weight as shown in the table.
Table 1
Table 2
Examples 1 to 6 and conjugated linoleic acid glyceride in comparative example 1~7 and medium chain triglyceride use microcapsule powder, Corresponding parts by weight are the parts by weight of microcapsule powder content.
Examples 1 to 6 is composition provided by the invention, when specifically used, can add 0.1%~2.0% glidant, such as Silica, calcium silicates, calcium monohydrogen phosphate can also further add 20%~40% corrigent, such as fruit powder, sugar alcohol.
In order to further prove that advantages of the present invention, the present invention provide the experiment number of Examples 1 to 6 and comparative example 1~7 According to prove advantages of the present invention.
Weight losing function human trial
The test method reference of this experiment《Health food is examined and assessment technique specification》Weight losing function in (version in 2003) The human feeding trial method of the method for inspection is carried out with operating instruction, and the simple obesity crowd that choosing meets tested standard participates in examination It tests, and is randomly divided into 14 groups, every group 50.Wherein 1 group is blank control, test-meal placebo, 2~7 groups of test-meal Examples 1 to 6 Described in composition, the composition of the composition described in 8~14 groups of test-meal comparative examples 1~7.1 group of active ingredient (i.e. table 1 With composition shown in each embodiment and comparative example in table 2) edible dosage be 0g/ times, 2~14 groups of effect ingredient (i.e. 1 Hes of table Composition shown in each embodiment and comparative example in table 2) edible dosage be 7.54g/ times, 3 times a day, continuously take 35 It.Weight, waistline (navel week), hip circumference are measured, and calculates constitutional index (BMI), overweight degree and body fat content and other effects property Index is carried out at the same time safety indexes, dietary factors and motion conditions observation.
Data analysing method：Itself test-meal is front and back relatively to use paired t-test；The each group use compared with blank control respectively Independent samples t-test；Multiple range test between different groups uses one-way analysis of variance.
Efficiency index measurement result is shown in Table 3~12.
Influence of 3 given the test agent of table to weight (kg)
Group Test-meal composition Before test-meal After test-meal Difference before and after test-meal
1 Placebo 82.34±5.94 82.63±5.67 -0.29±0.83j
2 Embodiment 1 82.73±6.26 80.28±6.09* 2.45±0.77※c
3 Embodiment 2 82.40±6.61 81.06±5.83* 1.34±0.79※d
4 Embodiment 3 82.18±6.49 80.85±6.64* 1.33±0.68※d
5 Embodiment 4 82.66±5.51 79.50±6.04* 3.16±0.91※b
6 Embodiment 5 82.77±6.82 78.44±6.75* 4.33±0.59※a
7 Embodiment 6 82.10±5.86 78.92±6.13* 3.18±0.64※b
8 Comparative example 1 82.15±5.90 81.84±6.19* 0.31±0.85※h
9 Comparative example 2 82.46±6.29 81.92±5.87* 0.54±0.65※g
10 Comparative example 3 82.28±6.15 81.96±6.09* 0.32±0.62※h
11 Comparative example 4 82.42±6.44 81.90±6.27* 0.52±0.76※g
12 Comparative example 5 82.13±5.98 81.21±5.93* 0.92±0.87※e
13 Comparative example 6 82.46±5.78 82.32±6.15* 0.14±0.69※i
14 Comparative example 7 82.37±6.13 81.61±5.24* 0.76±0.83※f
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 4 given the test agent of table to BMI
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 5 given the test agent of table to overweight degree (%)
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 6 given the test agent of table to waistline (cm)
Group Test-meal composition Before test-meal After test-meal Difference before and after test-meal
1 Placebo 101.68±4.10 101.55±4.05 0.13±1.27j
2 Embodiment 1 102.53±3.79 97.10±3.96* 5.43±1.09※c
3 Embodiment 2 102.28±4.04 99.22±4.16* 3.06±1.44※d
4 Embodiment 3 102.37±4.23 99.33±3.78* 3.04±1.23※d
5 Embodiment 4 102.36±3.85 96.19±4.13* 6.17±0.98※b
6 Embodiment 5 102.45±4.06 95.22±4.42* 7.23±1.15※a
7 Embodiment 6 102.62±3.92 96.47±3.95* 6.15±0.96※b
8 Comparative example 1 102.66±4.19 101.41±3.61* 1.25±1.34※g
9 Comparative example 2 102.54±4.15 101.68±4.28* 0.86±1.06※h
10 Comparative example 3 102.35±3.87 101.11±3.93* 1.24±0.89※g
11 Comparative example 4 102.56±4.01 101.69±4.29* 0.87±1.17※h
12 Comparative example 5 102.32±4.25 100.23±3.83* 2.09±0.86※e
13 Comparative example 6 102.44±3.76 102.12±4.15* 0.32±1.03※i
14 Comparative example 7 102.47±4.13 100.90±4.19* 1.57±0.79※f
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 7 given the test agent of table to hip circumference (cm)
Group Test-meal composition Before test-meal After test-meal Difference before and after test-meal
1 Placebo 106.49±3.42 106.33±3.09 0.16±1.84i
2 Embodiment 1 107.53±3.67 106.26±3.28* 1.27±1.72※c
3 Embodiment 2 107.35±3.19 106.46±3.39* 0.89±1.79※d
4 Embodiment 3 107.42±3.04 106.55±3.07* 0.87±1.38※d
5 Embodiment 4 107.33±3.46 105.08±3.15* 2.25±1.46※b
6 Embodiment 5 107.62±3.28 104.49±3.16* 3.13±1.39※a
7 Embodiment 6 107.29±3.26 105.06±3.23* 2.23±1.65※b
8 Comparative example 1 107.58±3.12 107.03±3.45* 0.55±1.66※g
9 Comparative example 2 107.29±3.25 106.87±3.12* 0.42±1.51※h
10 Comparative example 3 107.48±3.31 106.94±3.39* 0.54±1.28※g
11 Comparative example 4 107.18±3.57 106.75±3.30* 0.43±1.15※h
12 Comparative example 5 107.45±3.02 106.70±3.41* 0.75±1.27※e
13 Comparative example 6 107.63±3.47 107.29±3.28* 0.34±1.24※h
14 Comparative example 7 107.46±3.13 106.79±2.27* 0.67±1.31※f
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i) is compared between indicating different groups, is indicated different letters and is indicated have conspicuousness poor It is different, P ＜ 0.05
Influence of 8 given the test agent of table to body fat weight (kg)
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 9 given the test agent of table to mid-point fat thickness (mm) on the outside of right deltoid muscle lower edge arm
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 10 given the test agent of table to right angulus inferior scapulae fat thickness (mm)
Group Test-meal composition Before test-meal After test-meal Difference before and after test-meal
1 Placebo 40.01±3.69 40.20±4.22 -0.19±1.26j
2 Embodiment 1 40.23±3.75 37.66±3.97* 2.57±1.21※c
3 Embodiment 2 40.68±3.34 39.52±4.37* 1.16±0.97※d
4 Embodiment 3 40.19±3.05 39.05±3.92* 1.14±1.32※d
5 Embodiment 4 40.66±3.24 37.50±4.50* 3.16±1.14※b
6 Embodiment 5 40.19±3.47 35.57±4.45* 4.62±0.93※a
7 Embodiment 6 40.57±3.26 37.42±3.91* 3.15±1.08※b
8 Comparative example 1 40.37±3.16 39.63±4.42* 0.74±1.26※g
9 Comparative example 2 40.45±3.38 39.83±3.96* 0.62±1.15※h
10 Comparative example 3 40.32±3.52 39.59±3.98* 0.73±0.98※g
11 Comparative example 4 40.56±3.28 39.95±4.35* 0.61±0.87※h
12 Comparative example 5 40.48±3.65 39.55±4.17* 0.93±1.30※e
13 Comparative example 6 40.51±3.36 40.06±4.29* 0.45±0.96※i
14 Comparative example 7 40.28±3.08 39.47±4.49* 0.81±1.05※f
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 11 given the test agent of table to 3cm fat thickness (mm) by right navel
Group Test-meal composition Before test-meal After test-meal Difference before and after test-meal
1 Placebo 45.46±6.82 45.36±6.78 0.10±1.41j
2 Embodiment 1 45.70±6.75 43.10±6.21* 2.60±1.83※c
3 Embodiment 2 45.35±6.53 42.22±6.37* 1.13±1.57※d
4 Embodiment 3 45.28±6.33 44.04±6.43* 1.15±1.51※d
5 Embodiment 4 45.32±6.45 41.70±6.09* 3.62±1.64※b
6 Embodiment 5 45.61±6.29 41.49±6.15* 4.12±1.38※a
7 Embodiment 6 45.73±6.43 42.10±6.28* 3.63±1.54※b
8 Comparative example 1 45.18±6.17 44.47±6.09* 0.71±1.29※g
9 Comparative example 2 45.56±6.38 45.01±6.67* 0.55±1.46※h
10 Comparative example 3 45.29±6.67 44.59±6.53* 0.70±1.18※g
11 Comparative example 4 45.36±6.20 44.84±6.27* 0.52±1.05※h
12 Comparative example 5 45.44±6.34 44.46±6.45* 0.98±1.17※e
13 Comparative example 6 45.59±6.57 45.24±6.23* 0.35±1.33※i
14 Comparative example 7 45.34±6.42 44.52±6.36* 0.82±1.67※f
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Influence of 12 given the test agent of table to right bone Ant sup fat thickness (mm)
Note：* it indicates compared with before itself test-meal, P ＜ 0.05；※ indicates each group respectively compared with blank control, P ＜ 0.05；Alphabetical (a, b, c, d, e, f, g, h, i, j) is compared between indicating different groups, is indicated different letters and is indicated there is conspicuousness Difference, P ＜ 0.05
Meanwhile to safety indexes, dietary factors and motion conditions observation indicate that, composition provided by the present invention Have no adverse effects to human body, do not find adverse reaction during test-meal, and during experiment subject dietary structure It is not substantially change with moving situation, eliminates diet and movement acts on composition weight losing function provided by the present invention It influences.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered It is considered as protection scope of the present invention.

Claims (10)

1. a kind of composition, including：
2. composition according to claim 1, which is characterized in that the composition includes：
3. composition according to claim 2, which is characterized in that the composition includes：
4. according to the composition described in claims 1 to 3 any one, which is characterized in that further include one kind in following component Or it is several：
Beta-hydroxy -1.0~5.0 parts by weight of Beta-methyl calcium butyrate；
0.0001~0.0005 parts by weight of folic acid and/or folic acid derivatives.
5. composition according to claim 4, which is characterized in that further include one or more of following component：
Beta-hydroxy -2.0~5.0 parts by weight of Beta-methyl calcium butyrate；
0.0003~0.0005 parts by weight of folic acid and/or folic acid derivatives.
6. application of the composition in the product for preparing fat-reducing, increasing flesh described in Claims 1 to 5 any one.
7. a kind of product of fat-reducing, increasing flesh, which is characterized in that including the composition described in Claims 1 to 5 any one.
8. product according to claim 7, which is characterized in that its dosage form is pulvis, tablet, oral solution, granule and glue One or more of wafer.
9. product according to claim 8, which is characterized in that in the pulvis, including Claims 1 to 5 any one The glidant of the composition and 0.1%~2% weight percent.
10. product according to claim 9, which is characterized in that further include 20%~40% weight percent in the pulvis The corrigent of ratio.
CN201810295675.1A 2018-03-30 2018-03-30 A kind of product of composition, its application and fat-reducing, increasing flesh Pending CN108514119A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810295675.1A CN108514119A (en) 2018-03-30 2018-03-30 A kind of product of composition, its application and fat-reducing, increasing flesh

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810295675.1A CN108514119A (en) 2018-03-30 2018-03-30 A kind of product of composition, its application and fat-reducing, increasing flesh

Publications (1)

Publication Number Publication Date
CN108514119A true CN108514119A (en) 2018-09-11

Family

ID=63431350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810295675.1A Pending CN108514119A (en) 2018-03-30 2018-03-30 A kind of product of composition, its application and fat-reducing, increasing flesh

Country Status (1)

Country Link
CN (1) CN108514119A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111493312A (en) * 2020-04-10 2020-08-07 福建龙津堂健康产业有限公司 Coffee-flavored dietary nutrition meal and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310718A (en) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 Composition containing catechin for reducing weight and blood fat and use thereof
CN103190630A (en) * 2013-04-19 2013-07-10 广东太阳神集团有限公司 Functional protein powder containing conjugated linoleic acid glycerides
CN104026591A (en) * 2014-04-04 2014-09-10 上海英莱腾医药研究有限公司 Multifunctional protein food composition containing medium chain triglyceride
CN105054025A (en) * 2015-08-09 2015-11-18 青岛大学附属医院 Low-fat low-osmosis low-residue type enteral nutritional powder for patients with inflammatory bowel diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310718A (en) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 Composition containing catechin for reducing weight and blood fat and use thereof
CN103190630A (en) * 2013-04-19 2013-07-10 广东太阳神集团有限公司 Functional protein powder containing conjugated linoleic acid glycerides
CN104026591A (en) * 2014-04-04 2014-09-10 上海英莱腾医药研究有限公司 Multifunctional protein food composition containing medium chain triglyceride
CN105054025A (en) * 2015-08-09 2015-11-18 青岛大学附属医院 Low-fat low-osmosis low-residue type enteral nutritional powder for patients with inflammatory bowel diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111493312A (en) * 2020-04-10 2020-08-07 福建龙津堂健康产业有限公司 Coffee-flavored dietary nutrition meal and preparation method thereof

Similar Documents

Publication Publication Date Title
US5626849A (en) Weight loss composition for burning and reducing synthesis of fats
CN101061860B (en) Leucine-rich nutritional compositions
US10842839B2 (en) Natural formulation for treating hangover
JP4699901B2 (en) Dietary additive with body fat metabolism function and combustion energy utilization function
MXPA06012501A (en) Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite.
WO2011077800A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
CN101484158A (en) Senescence inhibitor
KR20150101458A (en) Synergistic dietary supplement for enhancing physical performance
CN102170798A (en) Composition for promoting control of total and LDL cholesterol and/or weight loss and/or thermogenesis
EP2859896A1 (en) Pharmaceutical compositions for the treatment of muscular disorders
WO2011096413A1 (en) Agent for improving motility function
CN103190483A (en) Children growth promotion milk tea
KR20240004452A (en) 1-Methylxanthine-based bioactive compositions and methods of using the same
EP3165221B1 (en) Blood-fat reducing composition and application thereof
CN102090453A (en) Weight-reducing and beautifying milk tea
CN108514119A (en) A kind of product of composition, its application and fat-reducing, increasing flesh
WO2013025201A1 (en) Method of transforming a meal
CN110584120A (en) Bone health composition
US6932987B1 (en) Chemical composition and method for enhancing metabolism
WO2019082335A1 (en) Inositol phosphate-containing composition
KR20180075423A (en) Composition comprising allulose for promoting discharge of vegetable lipids ex vivo
CA2446254C (en) New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits
RU2335927C2 (en) Nutrient compositions enriched with leucine
CN106036387A (en) Super chenopodium quinoa willd nutritional packet for promoting growth of children
KR100515923B1 (en) The bio conjugated proteins is process of produce

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180911